Jun 2020 $13 M No. 5 $10 to $50 million 24
Knopp Biosciences LLC: Raise no. 5, Jun 2020 × Investors in this round 24 investors had bought by the notice of Oct 27, 2020: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $26 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $472,888
Finders' fees none
Paid to its own people $2,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Calman A. Prussin · Executive Officer Gregory T. Hebrank · Executive Officer, Director, Promoter · LLC Manager James A. Mather · Executive Officer Mark A. Kreston · Executive Officer Michael E. Bozik · Executive Officer, Director, Promoter · LLC Manager Steven A. Dworetzky · Executive Officer Thomas V. Petzinger, Jr. · Executive Officer, Director, Promoter · LLC Manager Benjamin A. Gomez · Director · LLC Manager C. David Adair · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Stephen E Butts · Director · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Saturn Capital, Inc. (CRD 15412) · Boston, Massachusetts Sold in all US states Remarks in the notice On the amounts: “The offering amount takes into account the exercise of warrants”Signed by Gregory T. Hebrank, EVP, Corporate Operations & Finance. Source: SEC Form D and 1 amendment, newest notice filed Oct 27, 2020. Read the notice at the SEC .
equity, options SEC Mar 2020 $1 M No. 4 Under $2 million 1
Knopp Biosciences LLC: Raise no. 4, Mar 2020 × Investors in this round 1 investor had bought by the notice of Mar 5, 2020: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $520,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Calman A. Prussin · Executive Officer Gregory T. Hebrank · Executive Officer, Director, Promoter · LLC Manager James A. Mather · Executive Officer Mark A. Kreston · Executive Officer Michael E. Bozik · Executive Officer, Director, Promoter · LLC Manager Steve A. Dworetzky · Executive Officer Benjamin A. Gomez · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Thomas V. Petzinger, Jr. · Director, Promoter · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gregory T. Hebrank, EVP, Corporate Operations & Finance. Source: SEC Form D, newest notice filed Mar 5, 2020. Read the notice at the SEC .
debt, options SEC Feb 2019 $13 M No. 3 $10 to $50 million 26
Knopp Biosciences LLC: Raise no. 3, Feb 2019 × Investors in this round 26 investors had bought by the notice of Mar 2, 2020: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $26 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $263,750
Finders' fees none
Paid to its own people $4,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Calman A. Prussin · Executive Officer Gregory T. Hebrank · Executive Officer, Director, Promoter · LLC Manager James A. Mather · Executive Officer Mark A. Kreston · Executive Officer Michael E. Bozik · Executive Officer, Director, Promoter · LLC Manager Steven A. Dworetzky · Executive Officer Benjamin A. Gomez · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Thomas V. Petzinger, Jr. · Director, Promoter · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Saturn Capital, Inc. (CRD 15412) · Boston, Massachusetts Sold in all US states Remarks in the notice On the amounts: “Includes value of warrants issued and estimated value of warrants to be issued to the Placement Agent”Signed by Gregory T. Hebrank, EVP, Corporate Operations & Finance. Source: SEC Form D and 2 amendments, newest notice filed Mar 2, 2020. Read the notice at the SEC .
equity, options SEC May 2014 $28 M No. 2 $10 to $50 million 61
Knopp Biosciences LLC: Raise no. 2, May 2014 × Investors in this round 61 investors had bought by the notice of Jul 24, 2018: 61 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $28 M of $31 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $677,749
Finders' fees none
Paid to its own people $5,200,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Calman A. Prussin · Executive Officer Gregory T. Hebrank · Executive Officer, Director, Promoter · LLC Manager Michael E. Bozik · Executive Officer, Director, Promoter · LLC Manager Steven A. Dworetzky · Executive Officer Thomas V. Petzinger, Jr. · Executive Officer, Director, Promoter · LLC Manager Benjamin A. Gomez · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Stillpoint Capital, LLC (CRD 133146) · Tampa, Florida Sold in CA, CT, FL, MA, MD, NJ, NV, NY, OH, PA, and outside the US MIP Global, Inc. (CRD 164640) · Guaynabo, San Juan, Puerto Rico Sold in CA, CT, FL, MA, MD, NC, NJ, NV, NY, OH, PA, and outside the US Pickwick Capital Partners, LLC (CRD 130672) · White Plains, New York Sold in CA, CT, DC, IL, MA, MD, ME, NJ, NY, PA, TX, VA, WA Saturn Capital, Inc. (CRD 15412) · Boston, Massachusetts Sold in CT, FL, IL, KY, MA, NY, OH, PA, TX, WI Remarks in the notice On the amounts: “Includes warrants issued to the placement agent”Signed by Gregory T. Hebrank, EVP, Corporate Operations & Finance. Source: SEC Form D and 8 amendments, newest notice filed Jul 24, 2018. Read the notice at the SEC .
debt, options SEC Jul 2012 $15 M No. 1 $10 to $50 million 78
Knopp Biosciences LLC: Raise no. 1, Jul 2012 × Investors in this round 78 investors had bought by the notice of Jun 19, 2020: 78 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $30 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $2,500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Calman A. Prussin · Executive Officer Gregory T. Hebrank · Executive Officer, Director, Promoter · LLC Manager James A. Mather · Executive Officer Mark A. Kreston · Executive Officer Michael E. Bozik · Executive Officer, Director, Promoter · LLC Manager Steven A. Dworetzky · Executive Officer Benjamin A. Gomez · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Thomas V. Petzinger, Jr. · Director, Promoter · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The offering amount takes into account the exercise of warrants.”Signed by Gregory T. Hebrank, EVP, Corporate Operations & Finance. Source: SEC Form D and 8 amendments, newest notice filed Jun 19, 2020. Read the notice at the SEC .
equity, options SEC Aug 2010 $140 M Issued in a merger or acquisition $50 to $250 million 90
Knopp Biosciences LLC: Private sale, Aug 2010 × Investors in this round 90 investors had bought by the notice of Sep 3, 2010: 81 accredited, 9 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $140 M of $140 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Profits Interests
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Delaware People named in the notice Evan W. Ingersoll · Executive Officer Gregory T. Hebrank · Director, Executive Officer, Promoter · LLC Manager Michael E. Bozik · Director, Executive Officer, Promoter · LLC Manager Thomas W. Petzinger, Jr. · Director, Executive Officer, Promoter · LLC Manager Valentin K. Gribkoff · Executive Officer Benjamin A. Gomez · Director · LLC Manager Jeffrey S. McCormick · Director · LLC Manager Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “The securities were issued in connection with a merger.”Signed by Michael E. Bozik, President and CEO. Source: SEC Form D, newest notice filed Sep 3, 2010. Read the notice at the SEC .
equity SEC